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Abstract
Background: Tasquinimod (a quinoline-3-carboxyamide) is a small molecule immunotherapy with demonstrated
effects on the tumor microenvironment (TME) involving immunomodulation, anti-angiogenesis and inhibition of
metastasis. A target molecule of tasquinimod is the inflammatory protein S100A9 which has been shown to affect
the accumulation and function of suppressive myeloid cell subsets in tumors. Given the major impact of myeloid
cells to the tumor microenvironment, manipulation of this cell compartment is a desirable goal in cancer therapeutics.
Methods: To understand the consequences of tasquinimod treatment on the TME, we evaluated early treatment
effects in tumor infiltrating myeloid cells. Cellular phenotypes were studied by flow cytometry while gene expression
both in tumor tissue and in isolated CD11b+ cells or tumor cells were measured by real time-PCR. Effects on
angiogenesis were monitored by changes in CD31 levels and by gene expression in tumor tissue. Effects on
cytokine levels in tumor tissue and serum were determined by multiplex analysis.
Results: The MC38-C215 colon carcinoma tumors showed a substantial infiltration of primarily myeloid cells that were
dominated by Ly6ClowF4/80+CD206+ M2-polarized tumor associated macrophages (TAMs), an immuno-suppressive
and pro-angiogenic cell population. Here, we show that tasquinimod treatment induces an anti-tumor effect which is
subsequent to a reduction in tumor infiltrating CD206+ M2 macrophages and a simultaneous increase in M1
macrophages expressing MHC class II and CD86. The tasquinimod-induced changes in TAM polarization were
evident within 24 h of exposure, emphasizing the ability of tasquinimod to rapidly reprogram the tumor
microenvironment. This change in the tumor associated myeloid compartment preceded an increased IL12-production
within the tumor and a decrease in tumor neovascularization. The switch in TAM polarization by tasquinimod
was confirmed in the 4T1 breast cancer model where tasquinimod also reduce lung metastasis development.
Conclusion: Our data show that tasquinimod affects tumor infiltrating myeloid cells early after exposure, leading to a
change in phenotype from pro-angiogenic and immunosuppressive M2-like TAMs to pro-inflammatory M1-like
macrophages. These changes are consistent with the effects of tasquinimod seen on tumor vascularization,
immune suppression and metastasis giving further insights to the anti-tumor mechanism of action of tasquinimod.
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Background
During the last decades it has become evident that
pharmacological targeting of the tumor microenviron-
ment (TME) is of major importance for a successful
clinical outcome of anti-tumor therapies. Consequently,
a number of different therapeutic strategies are being de-
veloped to target the cells and molecules of the TME
[1–5]. The TME contains fibroblasts and endothelial
cells but also infiltrating lymphocytes and regulatory
myeloid cells such as myeloid derived suppressor cells
(MDSCs) and tumor associated macrophages (TAMs).
These multiple stromal cells constitute the primary
tumorigenic niche and their interactions are critical for
tumor growth and metastasis [6].
Macrophages are plastic cells and can be polarized
towards (i) classically activated, pro-inflammatory
M1 macrophages or (ii) alternatively activated, anti-
inflammatory and immune-suppressive M2 macro-
phages [7, 8]. M2 macrophages inhibit T cell activation by
e.g. depletion of L-arginine via arginase-1 (Arg-1) [9, 10],
express the mannose receptor C type 1 (Msr1; also
called CD206) and promote angiogenesis by express-
ing Tie-2 and by producing the pro-angiogenic factor
VEGF-A [11–13]. M1 macrophages on the other hand
produce anti-angiogenic cytokines such as IL-12 [14, 15]
and promote immune-mediated anti-tumor activity via
production of inducible nitric oxide synthase (iNOS) and
by high expression of MHC class II molecules [8]. Al-
though TAMs are usually depicted as M2 macrophages,
both forms can be found in the TME. Polarization seems
to depend on the nature of the TME where the
localization, type and origin of the tumor, hypoxia, other
infiltrating cells, and tumor produced factors is highly
associated with the phenotype and function of the infil-
trating TAMs [16]. Signaling through nuclear factor
kappa B (NF-κB) is considered of major importance for
macrophage polarization [10]. For instance, it has been
shown that sustained nuclear expression of p50 NFκB
homodimer results in a M2 phenotype [17], while by
targeting IKKβ and thereby inhibiting NF-κB activity,
M2 TAMs could be converted into macrophages of the
M1 phenotype [18, 19].
Tasquinimod (ABR-215050; a quinoline-3-carboxyamide)
is a small-molecule compound that has shown immuno-
modulatory [20, 21], anti-angiogenic [22, 23] and
anti-metastatic [24] properties in several experimental
tumor models. In a phase II clinical study, tasquini-
mod demonstrated improved progression free survival
compared to placebo in men with minimally symp-
tomatic metastatic castration-resistant prostate cancer
[25]. In a randomized placebo-controlled phase III
pivotal clinical study, tasquinimod reduced the risk of
radiographic cancer progression or death compared to
placebo (rPFS, HR = 0.69, 95 % CI: 0.60–0.80) in
patients with metastatic castration-resistant prostate can-
cer who had not received chemotherapy, but tasquinimod
did not extend overall survival (HR = 1.097, 95 % CI:
0.938–1.282) [26]. Tasquinimod interacts with and blocks
the function of two proteins that both are important for
signaling in the tumor microenvironment. One is the in-
flammatory protein S100A9 [20, 27] that can be secreted
as a Damage Associated Molecular Pattern (DAMP) to
interact with receptors such as TLR4, RAGE and CD147
(EMMPRIN) on myeloid and other cells. S100A9 has been
demonstrated to affect the accumulation and function of
CD11b+Gr1+ regulatory myeloid cells [28, 29], and has
multiple functions in macrophage subsets [30]. Another
molecular target for tasquinimod is histone-deacetylase-4
(HDAC4) that is involved in HIF1α-signaling. Binding of
tasquinimod to HDAC4 prevents it from forming an ac-
tive complex with NCoR/HDAC3 and inhibits HDAC4
client transcription factors such as HIF-1α [31].
Tasquinimod treatment leads to changes in the num-
ber and frequency of tumor-infiltrating regulatory mye-
loid cells and reduces the immune suppressive potential
of the TME [21, 24]. In this study, we extended the ana-
lysis of consequences of tasquinimod treatment on the
TME looking at early changes in myeloid cells after
treatment. Surprisingly, tasquinimod treatment altered
the TAM population in the tumor as early as 24 h after
initiating treatment in the MC38-C215 colon tumor
model. Increased levels of IL-12 could be detected
within the tumor after 5 days which preceded changes
in the vasculature of the tumor. Macrophages isolated
from tumors at the end of the experiment showed
changes in both gene expression and function that
reflected a shift from M2 to M1 macrophages. This
phenotypic switch was confirmed in the 4T1 mammary
tumor model where it also preceeded a reduction in
lung metastasis. Thus, tasquinimod treatment induced
a prompt and robust effect on myeloid cells in tumors.
Given the major contribution of tumor-infiltrating mye-
loid cell populations to angiogenesis, immune suppres-
sion and metastatic potential of a tumor, these findings
provide more insights into the effects of tasquinimod in
these processes. This study also highlights the adapt-
ability of the TME by showing the possibility to induce
early changes in TAM polarization in vivo by inhibition
of signals important to maintain the pro-tumoral func-
tions of the TME.
Results
Tasquinimod treatment impairs MC38-C215 tumor growth
in vivo
Tasquinimod has previously demonstrated potential
therapeutic benefit in several xenograft tumor models
which has been mainly linked to its anti-angiogenic
properties [22]. However, in a recent study in two
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different syngeneic tumor models, tasquinimod was
shown to modulate myeloid cells, leading to a reduc-
tion in tumor immunosuppression and increased efficacy
of two different immunotherapies [21]. To further study
these changes and to investigate the crosstalk between
tasquinimod's immunomodulatory and anti-angiogenic
properties, experiments were performed in the MC38-
C215 tumor model, a variant of the syngenic MC38
colon carcinoma model which has a strong component
of TAMs with a predominance of the M2-phenotype
[32]. We demonstrated here that tasquinimod treat-
ment led to a significant inhibitory effect on MC38-
C215 tumor growth after subcutaneous inoculation of
tumor cells (Fig. 1a). In contrast to its effect on MC38-
C215 tumor growth in vivo, tasquinimod had no direct
effect on MC38-C215 cell proliferation in vitro, neither
under normoxic or hypoxic growth conditions (Fig. 1b).
The anti-tumor effect in vivo did not correlate with an
increased T cell infiltration since only a few CD4 or
CD8 positive cells were observed in the MC38-C215
tumors at end-point without significant differences be-
tween control and tasquinimod treated tumors (unpub-
lished observations). However, the treated tumors
showed a significant reduction in microvessel density as
detected by CD31 staining (Fig. 1c). Thus, tasquinimod
inhibits growth of MC38-C215 tumors in syngeneic
mice via an effect that does not correlate to a general
inhibition of tumor cell proliferation, nor to an increased
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Fig. 1 Tasquinimod impairs tumor growth in vivo and reduces the microvascular density in MC38-C215 tumors. a Wild type mice were inoculated
s.c. with 0.5 × 106 MC38-C215 cells. Treatment with tasquinimod (30 mg/kg ad lib.) was initiated on the day of tumor inoculation and continued
throughout the experiment. Tumor volumes (left panel) were measured every 2-3 days from day 7 and the experiment was terminated on day 14
(*p = 0.029; two-way ANOVA, Error bars indicate s.e.m) and tumor weights (right panel) at the end of experiment (*p < 0.05; Mann Whitney). b No
effect on MC38-C215 proliferation in vitro. MC38-C215 cancer cells (5000 cells/well) were seeded in 96 well plates and the cultured cells treated
with tasquinimod for 72 h under either normoxic (left panel) or hypoxic (right panel) growth conditions. Viability was determined by MTT assay
at the end of incubation. c CD31 staining is significantly different between tumors from control and tasquinimod treated animals: Left-control
group tumor, right-tasquinimod group tumor. Vascular density determined as percentage of stained area compared to total tumor area (* p < 0.05;
Mann Whitney, Error bars indicate s.e.m)
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T cell infiltration, but that does correlate to a change in
vascularization of the tumor.
Tumor-infiltrating TAMs are functionally skewed from a
M2 to a M1 phenotype after tasquinimod treatment
Tasquinimod has shown effects on myeloid cells in
other experimental tumors [21] and given the major
contribution of regulatory myeloid cells to tumor angio-
genesis [2], we analyzed the consequence of tasquinimod
treatment on the myeloid cell compartment in the spleen
and in the tumor. The frequency of CD11b-expressing
cells in the tumors was not affected by tasquinimod treat-
ment for 14 days (Fig. 2a). The CD11b+ compartment in















































































































































































Fig. 2 CD11b+F4/80+ infiltrating cells are functionally skewed from a pro-tumor CD206+ M2 phenotype into a CD206− anti-tumor M1 phenotype
after tasquinimod treatment. Modulation of myeloid CD11b+ subpopulations in MC38 tumors by tasquinimod. a Percent CD11b+ cells of infiltrating
cells, b representative FACS plots F4/80+CD206+ staining of tumor infiltrating CD11b+ cells, c F4/80+ cells as frequency of total CD11b+
cells, d frequency of CD206+ cells in tumors ± tasquinimod treatment (**p < 0.01; two-way ANOVA, Error bars indicate s.e.m) and e frequency of
Ly6ChighLy6G− and Ly6G+ cell populations in tumor. f Up-regulation of M1 markers and down-regulation of M2 markers in infiltrating CD11b+F4/80+
after tasquinimod treatment. Tumor infiltrating CD11b+F4/80+ cells were isolated from MC38-C215 tumors at day 14, FACS-sorted and qRT-PCR was
performed on the indicated genes. g Infiltrating F4/80+ cells are less immune suppressive after tasquinimod treatment. CD4+ T cells were stimulated
with αCD3 and α CD28 in the presence of F4/80+ cells at indicated ratios (F4/80:CD4) and proliferation was measured by 3H-thymidine incorporation
(**p < 0.01 and ***p < 0.001; t-test, Error bars indicate s.e.m)
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and the majority of the cells in the untreated tumors
also expressed CD206 (Fig. 2b, left panel). F4/80 and
CD206 together mark M2-skewed TAMs, that have
both immunosuppressive and pro-angiogenic functions.
Treatment with tasquinimod changed the CD11b+F4/
80+ population from a CD206+ to a mainly CD206−
population at the experimental endpoint (day 14)
(Fig. 2b-d), indicative of a shift from immunosuppres-
sive M2 to pro-inflammatory M1 macrophages. While
F4/80+ cells were the dominating population of the
tumor infiltrating myeloid cells, the granulocytic Ly6G+
and monocytic Ly6Chigh MDSC subpopulations were
only found at low levels in the tumor and were not sig-
nificantly altered by tasquinimod treatment (Fig. 2e).
To further investigate the M2 to M1 switch induced by
tasquinimod, a similar analysis was performed in the
orthotopic breast cancer model 4T1. Tasquinimod
treatment in this model reduced tumor growth and also
the number of lung metastatic nodes after orthotopic
injection of 4 T1 tumor cells into the mammary fat pad
of Balb/c mice (Additional file 1: Figures S1A and S1B).
As in the MC38-C215, the total population of tumor
infiltrating CD11b-positive cells and the frequency of
infiltrating CD11b+F4/80+ did not change after treat-
ment, whereas a tasquinimod-induced shift from a
CD206-positive to CD206-negative phenotype could be
determined (Additional file 1: Figures S1C-E) and the
shift sustained over time and seemed to be independent
of tumor size (Additional file 1: Figures S1G and
Fig. 1a). In contrast to the MC38-C215 tumors though,
the infiltrating CD11b+ component in 4T1 tumors was
mainly Gr1+ cells and Ly6ClowLy6G+ cells was the dom-
inating population which was not affected by the tas-
quinimod treatment (Additional file 1: Figure S1F).
To study functional and genetic changes in the tumor-
infiltrating macrophages we performed mRNA-analysis
of the CD11b+F4/80+ cells by qRT-PCR. The CD11b+F4/
80+ population from MC38-C215 tumors of treated mice
had up-regulated mRNAs of genes characteristic of M1
macrophages (i.e. Nos2, Cxcl9, Cxcl11, Il-12β and Il-6)
[33], whereas mRNA for genes typical for immunosup-
pressive cells of the M2 phenotype (i.e. CD206 & Arg-1;
Fig. 2f and Additional file 7; Table S1) were down-
regulated. Similarly, a decrease in the expression of
different M2-associated genes (i.e CD206 & Arg-1;
Additional file 1: Figure S1G) was observed in 4T1
tumors treated with tasquinimod for 14 or 28 days.
M2 TAMs have a high capacity to suppress T cell prolif-
eration by several mechanisms, including high expression
of arginase-1 (Arg-1) which acts to deplete L-arginine in
the tumor. The funtionality of the CD11b+F4/80+ cells
was investigated by determining their capacity to suppress
T cell proliferation ex vivo. Naïve CD4+ T cells were stim-
ulated with anti-CD3/CD28 antibodies in the presence of
FACS-sorted CD11b+F4/80+ cells from treated or un-
treated MC38-C215 tumors. The analysis showed that
macrophages from tasquinimod-treated mice were less
able to suppress T cell proliferation compared to macro-
phages from control mice (Fig. 2g). These results com-
bined show that the TAM population in tumors from
tasquinimod-treated mice are functionally skewed towards
the M1-like phenotype while control tumors contain a
myeloid cell population dominated by M2 macrophages.
The number of splenic CD11b+ myeloid cells was sig-
nificantly increased in MC38-C215 tumor bearing mice
compared to non-tumor bearing mice, but in contrast to
what was observed in the tumor, this expansion was pre-
vented by tasquinimod treatment (Additional file 2: Figure
S2A). However, in tasquinimod treated naïve mice the
CD11b+ cell population did not significantly change in the
spleen confirming that the observed increase in tumor
bearing mice was a tumor related event inhibited by tas-
quinimod treatment (Additional file 2: Figure S2B).
Changes in the tumor microenvironment are established
within a week after initiating tasquinimod treatment
In order to map effects of tasquinimod on the TME,
microvascular density was determined by anti-CD31
staining after treatment of established tumors for 1, 3, 5
or 7 days before termination of the experiment 10 days
after inoculation (Fig. 3a, left upper panel). No signifi-
cant anti-tumor effects were observed after short-term
exposure (data not shown), whereas a significant reduc-
tion in vascular density was induced within 7 days of
tasquinimod exposure (Fig. 3a). This was further empha-
sized by mRNA analysis of whole tumor preparations,
where a significant elevation in hypoxia-related genes
(i.e. Glut-1 (Slc2a1), Angpt2, Stc2, and Semaphorin B)
could be seen coinciding with reduced CD31-staining
(Fig. 3a and b; Additional file 8: Table S2). This indicates
onset of an angiogenic switch concomitant with reduced
microvascular density, increased hypoxia and induction
of Hif-1α-controlled genes. Expression of CD206 and
Nos2 were analyzed in tumor samples as markers of M2
and M1 related genes respectively. A decrease in CD206
(Mrc1) and an increase in Nos2 (Fig. 3c; Additional file
8: Table S2) expression could be seen in the TME before
or in connection with the changes in CD31 staining and
hypoxia-regulated genes. Hence, tasquinimod-induced
changes in the TME including vascularization, hypoxia
and immune-related genes are established within the
first week of treatment.
Tasquinimod treatment results in phenotypic changes
of myeloid cells in the tumor at early time points after
exposure
In order to study early changes in the myeloid cells spe-
cifically, analysis of purified CD11b+ cells from tumors
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treated with tasquinimod for 1 and 3 days was per-
formed. Already after short-term exposure, the F4/80+
macrophages displayed reduced cell surface expression
of CD206, and an upregulation of MHC class II and
CD86 (Fig. 4a; Additional file 3: Figure S3), indicating an
impact on the cellular activation state already after 1 day
of exposure in vivo. The cellular changes were further
emphasized when analyzing mRNA levels from the iso-
lated cells. Here, a change in Fn1 and Il-10 expression
was observed after 1 day of treatment while only minor
changes in mRNA levels for CD206 and Arg-1 (Fig. 4b;
Additional file 9: Table S3) could be seen. Interestingly,
in the CD11b+ cells a significantly decreased expression
of the pro-angiogenic factors Vegfc, Fgf2, Nrp1 and Il-6
was clearly evident at these early time points (Fig. 4c).
These results show that tasquinimod treatment induces
early changes of the myeloid cell population that lead to
upregulation of inflammatory markers and a down-
regulation of pro-angiogenic factors. These changes are
consistent with an initiation of a change in phenotype
from an M2-like TAM to a M1-like macrophage.
To further analyze the functional changes of the infil-
trating CD11b+ cells after treatment, isolated cells from
tumors were activated ex vivo by culturing for 24 h in
c
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Fig. 3 Tasquinimod induces tumor immunomodulation and inhibits tumor angiogenesis within one week of exposure. a CD31 staining of tumors
from control and tasquinimod treated animals. Mice were treated for 1, 5 or 7 days with tasquinimod (p.o.; 30 mg/kg/day). b Hypoxia-induced
expression of Hif-1α controlled genes in tumor samples; SemaphorinB (left panel) and Glut-1 (right panel) after 7 days of exposure. c Time study
of mRNA expression in tumors treated with tasquinimod for 1 up to 7 days of exposure CD206 (Mrc1) (left panel) and Nos2 (right panel) (versus control;
* p < 0.05; ** p < 0.01 and *** p < 0.001; One way ANOVA with Dunnetts multiple comparison test, Error bars indicate s.e.m)
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medium ± LPS/IFNγ and induction of Arg-1 or Il12β
gene expression was studied. M1 macrophages produce
IL-12 in response to this stimulation [33, 34] while
arginase-1 is an effector molecule and signature of M2
macrophages. qRT-PCR analysis of cells after induction
revealed that isolated CD11b+ cells from vehicle-treated
MC38-C215 tumors expressed high levels of Arg-1
mRNA while isolated cells from tasquinimod treated
mice had completely lost the capability to induce Arg-1
(Fig. 5a). On the other hand, CD11b+ cells from
tasquinimod-treated mice induced high levels of Il12β
whereas CD11b+ cells from vehicle did not respond at
all to the same extent. This experiment shows that tas-
quinimod treatment induces functional changes of
tumor associated myeloid cells already after 1-3 days of
treatment (Fig. 5a).
In order to verify the relevance of these changes in
vivo, protein determination by a multiplex assay
(Millipore) was performed on tumor tissue lysates. 12
proteins were analyzed (Additional file 10: Table S4) and
of these IL-12(p40) levels were significantly higher after
5 and 7 days of tasquinimod treatment (Fig. 5b). This
was also accompanied by significantly increased serum
levels of IL-12(p40) (Additional file 4: Figure S4).
Discussion
Tumors devise different mechanisms to shape their
microenvironment to allow growth and to evade anti-
tumor immune responses. Among them, infiltrating
TAMs promote tumor progression and metastasis [7]
and are commonly recognized as obstacles to various
anti-cancer therapies [35]. We recently showed that
tasquinimod reduces the ability of suppressive myeloid
cells, including TAMs, to support tumor growth and
significantly enhances the efficacy of cancer immuno-



















 MHC class II expression






























































































Fig. 4 M1 macrophages, induced by tasquinimod modulates the expression of different angiogenic factors. a Median Fluorescence Intensity
(MFI)values of CD206, MHC-II and CD86 cell surface expression evaluated by flow cytometry on isolated tumor infiltrating CD11b+ cells gated on
the F4/80high population after 1 and 3 days of in vivo exposure to tasquinimod. Results from one out of three representative experiments are
shown. b Up-regulation of M1 genes Nos2 (iNos) and Il-12β, and down-regulation of M2 genes CD206, Arg-1 and Il-10 mRNA expression in isolated
tumor infiltrating CD11b+ cells after 1 and 3 days of in vivo exposure to tasquinimod. c Changes of pro-angiogenic genes Vegfa, Vegfc, Fgf2, Nrp1
and Il-6 mRNA expression in isolated tumor infiltrating CD11b+ cells after 1 and 3 days of in vivo exposure to tasquinimod (versus control; * p < 0.05;
** p < 0.01 and *** p < 0.001; One way ANOVA with Dunnetts multiple comparison test, Error bars indicate s.e.m)
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events regulated by tasquinimod to exert this immuno-
modulatory activity, we took advantage of the MC38-
C215 colon cancer model in which F4/80+ macrophages
constitute the dominant myeloid cell population [32].
Circulating monocytes are recruited by tumors, and de-
pending on the inflammatory state of the tumors, they
may differentiate into M1 or M2 macrophages, gaining
specialized functional properties. Moreover, during
tumor progression, MDSCs accumulate in blood and in
spleen and are also recruited to the TME, where they
accumulate and may also differentiate to M1 or M2
macrophages [36–38]. M1 macrophages produce higher
levels of pro-inflammatory IL-12 and lower levels of
anti-inflammatory IL-10 [39]. They also produce ef-
fector molecules, such as iNOS, which contribute to
the Th1 response in the TME. Our findings show that
tasquinimod changes the polarization of macrophages
in the tumor by several different parameters, such as an
increase in MHC class II, CD86 and Nos2 expression
and a reduced arginase-1 and CD206 expression. These
results confirm that tasquinimod induces a shift from
immunosuppressive M2 macrophages to immunostimu-
latory M1 macrophages in the MC38-C215 tumor model,
in agreement with previously published data in experi-
mental models of prostate cancer and melanoma [21].
The increased expression of M1 markers in macro-
phages after tasquinimod treatment raises the question
whether tasquinimod increases the recruitment of cir-
culating monocytes and myeloid cells, and/or their dif-
ferentiation into M1 macrophages and accumulation in
the TME. Tumor infiltration of TAMs is often mastered
by the Ccl2 chemokine that attracts Ccr2+ monocytes
circulating in the blood [10], but in this study the ex-
pression of Ccl2 mRNA (Additional file 8: Table S2)
and its encoded protein MCP-1 (Additional file 10:
Table S4) in tumors were not modulated by treatment
and hence cannot explain the effects on TAMs. On the
other hand, S100A9 is also known to affect migration
of myeloid cells and MDSCs in particular into tumor
tissue [29]. Thus binding of tasquinimod to S100A9,
and thereby inhibiting its interaction with receptors on
myeloid cells, is a possible mechanism for an altered
migration of myeloid cells into the tumor. In the
MC38-C215 tumors, however, the myeloid compart-
ment of the TME was dominated by F4/80+ macro-
phages and this composition was stable over time and
with respect to tumor size (from day 7 to day 14, data
not shown). Since the effect of tasquinimod treatment
was a change from F480+CD206+ to F4/80+CD206−
macrophages without changing the total frequency of
F4/80+ cells, this would require a rapid turnover of
macrophages in the tumor to explain the treatment ef-
fects. However, since M2 macrophages are known to be
a relatively stable subset of myeloid cells in the TME
not undergoing constant replenishment [7, 40] we
strongly believe this is unlikely and that tasquinimod
rather induces a rapid change in polarization of the
existing macrophages in the tumor. Instead, S100A9 is
known to induce NF-κB activity [41], and targeting NF-κB
in colon cancer cells educates macrophages toward a
M1-like phenotype and inhibits peritoneal metastasis
[42]. These latter data support a hypothesis where
S100A9 sustains NF-κB activation by interaction with
receptors such as TLR4, and where tasquinimod by
blocking S100A9-receptor interactions, decreases NF-κB
activity and induces a polarization of macrophages to-
ward the M1 phenotype. Moreover, rapid changes
from a M2 to a M1 phenotype of infiltrating macro-
phages was reported by Guiducci et al. [43], that in
Ccl16-treated TSA mammary carcinoma tumors ob-
served changes in polarization within less than 16 h,































































































Fig. 5 Tasquinimod-induced functional changes in tumor derived
CD11b+. a Changes of Arg-1 and Il-12β mRNA levels in isolated
tumor infiltrating CD11b+ cells stimulated with LPS/IFNγ and cultured
ex vivo for 24 h. Results from one out of three representative
experiments are shown (* p < 0.05; t-test, Error bars indicate s.e.m).
b IL-12(p40) cytokine production of tumor lysates prepared from
treated and non-treated tumors (*p < 0.05 Jonckheere-Terpstra
test; Error bars indicate s.e.m)
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CpG and an anti-IL-10 receptor antibody. Taken to-
gether our findings suggest that tasquinimod may not
primarily trigger a difference in the recruitment of
F4/80+ myeloid cells, but may rather change their dif-
ferentiation state within the MC38-C215 tumors. Irre-
spective of the diversity of myeloid cells present in
the tumor microenvironment, we demonstrated that
tasquinimod was able to induce a long-term education of
macrophages from a M2 to a M1 phenotype in 4T1 tu-
mors. These findings were associated with a prolonged in-
hibition of 4T1 tumor growth over 28 days and with a
reduction in lung metastasis development.
Although reduced immunosuppression is one conse-
quence of macrophage M1-polarization, tasquinimod
inhibited MC38-C215 tumor growth in immune defi-
cient nude mice by the same magnitude as in the
wild type mice (Additional file 5: Figure S5), indicat-
ing that the tasquinimod-induced antitumor effect is
not due to a change in the T cell response. In accord-
ance with this, whilst tasquinimod did affect the sup-
pressive potential of MC38-C215 TAMs this did not
lead to an increased recruitment of T cells into the
tumors in vivo. However, a number of factors influ-
ence T-cell tumor infiltration and TAMs may not be
the prime obstacle for T-cells to reach the MC38-C215 tu-
mors. Indeed, several studies from the literature have re-
ported that the expression of immune checkpoints
inihbitors in the TME such as the PD-1/PD-L1 axis may
limit T cell infiltration and expansion [44].
Instead, substantial changes in vascularization in the
tumor could be observed after a week of treatment
with tasquinimod. Since CD11b+MHC-IIlow cells pre-
viously have been shown to be pro-angiogenic in dif-
ferent mouse tumor models with a common gene
profile [33], the shift from a MHC-IIlow into a MHC-
IIhigh profile seen in this study also reflects a change
into TAMs with a less pro-angiogenic M1 phenotype
after treatment with tasquinimod (Additional file 9:
Table S3). Interestingly, 24 h after tasquinimod expos-
ure, mRNA expression of different angiogenic factors
(Vegfc, Nrp-1, Fgf2, Il-6) was decreased in MCH-IIhigh
macrophages compared to vehicle TAMs, suggesting
that M1 macrophages contribute to tumor vasculature
shrinkage. Indeed, using syngeneic mice bearing MC38-
CEA tumors, Farsaci et al. showed the presence of
CD31+ and CD105+ tumor vessels formed after trans-
ferring CD11b+ myeloid cells, confirming that tumor
vessels are modulated by cells of monocytic origin [32].
Furthermore, it has recently been shown that tumor-
derived S100A9 induced the production of IL-6 by
myeloid cells in ovarian tumors [45], and that IL-6
drives angiogenesis with defective pericyte coverage
typical for TME [46]. Moreover, different cellular assays
showed that tasquinimod did not inhibit the kinase
driven angiogenesis from the following proteins: EGF-R,
FGF-R2, IGF1-R, c-kit, Met, SRC, Tie2, VEGF-R2 and
VEGF-R3 (Additional file 11: Table S5). Also, tasquini-
mod was not able to suppress VEGF-A induced angio-
genesis in vitro, in contrast to anti-VEGF or suramin
treatment (Additional file 6: Figure S6). These data valid-
ate that tasquinimod has a unique mechanism of action
that is completely different from classical anti-angiogenic
and tyrosine kinase inhibitor drugs. In addition to S100A9
and its importance for macrophage signaling and angio-
genesis, an alternative molecular target for tasquinimod
is HDAC4, where the inhibition of HDAC4 interaction
with NCoR/HDAC3 has been shown to inhibit the
transcription of HIF-1α-controlled genes such as VegfA
[31]. HIF-1α signaling in response to hypoxia has been
described as important for myeloid cell function in the
TME, but although tumor hypoxia and HIF-1α regulate
MDSC differentiation [10, 47], hypoxia does not seem
to be the major driver of TAM differentiation into pro-
angiogenic M2 subsets. Instead, HIF-1α specifically reg-
ulates expression of pro-angiogenic factors such as
VegfA and Glut1 in already differentiated M2 TAMs
[37, 48]. Thus, defective microvessel formation in
treated MC38-C215 tumors are likely related to down-
regulated expression of a set of pro-angiogenic genes in
macrophages. This report is the first to unveil the se-
quence of events regulated by tasquinimod demonstrat-
ing that immunomodulatory properties of the tumors
are the first to be modulated after exposure, which in
turn may drive its anti-angiogenic activity.
To gain more insight into macrophage driven angio-
genesis inhibition in our experimental model, macro-
phages derived from tumors exposed to tasquinimod
for 1 day or 3 days were stimulated with the classical
M1 activators LPS and IFNγ. Interestingly, Arginase-1
mRNA expression was substantially decreased after
tasquinimod treatment, indicating a shift of TAMs into
the M1 phenotype. Li et al. showed that over-expression
of Arginase-1 increased HUVEC proliferation and pro-
moted tube-like morphogenesis, suggesting that Arginase-
1 plays an important role in the process of angiogenesis
[49]. Moreover, an increase in Il-12β expression was ob-
served in macrophages treated with tasquinimod. The
mechanisms of Il-12-mediated antitumor activity depend
not only on activation of innate and adaptive effector im-
mune mechanisms, but also on inhibition of angiogenesis
[14, 15, 51]. In tumors treated with tasquinimod, produc-
tion of IL-12 (p40) was high in the TME after 5 to 7 days
of tasquinimod exposure with a concomitant decrease in
CD31 immunostaining.
Macrophages exert their antitumor effects by i) pro-
ducing anti-angiogenic and cytotoxic cytokines and by
ii) orienting the adaptive immune response by pre-
senting MHC-II–bound peptides to T cells [11, 51].
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Tasquinimod modulates both mechanisms triggered by
macrophages to mediate antitumor activity. Thus, tas-
quinimod treatment impairs tumor growth and is asso-
ciated with a reduction in the microvascular density of
MC38-C215 tumors. An early switch of macrophages
may precede several mechanisms that are involved in
tumor progression and metastasis. We demonstrated
here that the anti-angiogenic as well as the anti-
metastatic effects of tasquinimod are preceded by an
early switch of tumor macrophages into a less suppres-
sive and anti-angiogenic population. This was mani-
fested by a decrease of pro-angiogenic markers and the
increase of anti-angiogenic IL-12 production in MC38-
C215 tumors. However, further analysis are needed to
address the direct link between the immunosuppressive
properties of myeloid cells and their ability to inhibit
tumor vessel formation and metastatic spread.
Conclusions
In this study, we demonstrate a significant antitumor
effect by tasquinimod treatment which associates with
early effects on tumor infiltrating myeloid cells leading
to a change in phenotype from pro-angiogenic and im-
munosuppressive M2-like TAMs to pro-inflammatory
M1-like macrophages. These changes are consistent
with the effects of tasquinimod previously seen on
tumor vascularization, immune suppression and metas-
tasis [21, 24] and highlights tasquinimod as an immu-
nomodulatory anti-tumor agent. Modulating tumor-
infiltrating macrophages and other myeloid cells is an
important piece in establishing therapeutic strategies to
overcome tumor immune evasion, progression and me-
tastasis development. Our findings further highlight the
potential of educating macrophages to eradicate tumors




Female C57Bl/6 mice were purchased from Taconic
Europe A/S (Denmark), and maintained under stan-
dardized conditions. Female Balb/c mice were pur-
chased from JANVIER LABS (France). The mice were
routinely used at the age of 8 to 12 weeks. All studies
were approved by the Bioethics Committee in Lund,
Sweden (M60-10 and M450-12), the Bioethics Committee
of IPSEN (C2EA-13-048-S1) and by the French ministry
(00617.01). All the experiments were conducted in
accordance with the NIH Guide for the Care and Use of
Laboratory Animals. Mice were treated with tasquinimod
(30 mg/kg) ad lib. via drinking water or in the case of
time studies by p.o. administration. The 4 T1 tumor cells
were purchased from ATCC (France). The MC38 tumor
cell line was obtained from S. A. Rosenberg (Nat. Cancer
Inst., Bethesda, Maryland) and was transfected with the
C215 antigen as previously described [52]. The cells
were cultured in RPMI-1640 supplemented with ultra-
glutamine (BioWhittaker/Lonza, Wokingham, UK); 10 %
fetal bovine serum (Fisher Scientific, Pittsburgh, PA), 1 mM
sodium pyruvate, 10 mM HEPES, 0.2 mg/ml gentamicine
sulfate and 50 μM β-mercaptoethanol (R10 medium).
In vivo tumor experiments
MC38-C215 cells were cultured as described above,
counted and re-suspended and maintained in ice cold
matrigel (BD Biosciences, San Jose, CA) at a concen-
tration of 5 × 106 cells/ml for subcutaneous inocula-
tion. The tumor cells were implanted s.c. into the
hind flank of mice on day 0 in a volume of 0.1 ml
matrigel. 4T1 cells (105) were injected orthotopically
into the fourth mammary fat pad of Balb/c mice.
Mice were treated ad lib or in the case of time stud-
ies by p.o.with tasquinimod dissolved in the drinking
water (30 mg/kg) for indicated times. The tumor size
was measured by a caliper twice a week. Tumor vol-
ume (V) was calculated using the following equation:
(width)2 × length/2, both in millimeters.
Cell sorting and FACS analysis
Single cell suspensions were prepared from spleens and
from tumors by incubating the tumors cut into small
pieces in 1.6 mg/ml Collagenase IV (Worthington Bio-
chemical Corporation, Lakewood, NJ) and 0.1 % DNase
(Sigma-Aldrich, St. Louis, MO) for 45 min at 37 °C,
followed by meshing the tumors in a 70 μm cell strainer.
CD11b+ cells were further purified from tumor cell sus-
pensions by magnetic depletion of MC38-C215 tumor
cells after incubation with anti-C215-biotin (10 μg/ml)
and Dynabeads® Biotin Binder beads (Life Technologies)
followed by positive selection of CD11b+ cells by MACS
technology (Miltenyi).
Before incubating the cells with specific fluorochrome-
labeled antibodies, Fc-receptors were blocked using anti-
CD16/CD32 mAb (clone 2.4G2; BD Biosciences). The
following fluorochrome-labeled antibodies were used:
CD11b (clone M1/70), Ly6G (clone 1A8), Ly6C (clone
AL-21), F4/80 (clone BM8), CD206 (clone C068C2),
CD86 (clone GL1), MHC II (I-A/I-E; clone M5/
114.15.2), CD4 (clone RM4-5), and CD8a (clone 53-6.7),
purchased from BD Biosciences (San Jose, CA),
eBioscience (San Diego, CA) and BioLegend (San Diego,
CA). Intracellular staining of CD206 was performed
using the Mouse Regulatory T cell Staining Kit from
eBioscience. Flow cytometric analysis was performed
according to standard settings on a FACS CantoII flow
cytometer (BD Biosciences).
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Histology
Tumors were sampled at different time points (1, 3,
5, or 7 days after initiation of treatment), weighted,
embedded in OCT (Optimal Cutting Temperature)
compound and snap frozen in pre-cooled isopentane
in liquid nitrogen before storage at -80 °C. Tumors
were sectioned for protein extraction (one 1000 μm-thick
section), RNA extraction (one 100 μm thick section) or
histology (8 μm thick sections) using a cryostat (Leica,
CM 3050S). One slide per tumor was stained with HE in
order to evaluate tumor morphology. CD31 immuno-
histochemical staining was performed with rat anti-
CD31 monoclonal antibody (AbD Serotec, MCA1212)
and peroxidase/diamminobenzidine revelation. Vascu-
lar density was evaluated for 3 regions of interest per
tumor by measuring the percentage of stained area by
image analysis using Image J software (MBF Image J
1.34 m). Formalin-fixed, paraffin-embedded mouse
lung tissue sections were prepared and 5 μm sections
were examined using H&E staining. Slides were scanned
(Excilone - France) and image analysis was performed
using a software, Halo (Indica Labs). Tumor infiltration in
the lungs was characterized by manual segmentation of
tumor nodules on digital whole slide at ×2 magnification.
Metastatic burden was quantified by counting the total
number of metastatic lung nodes in each section.
In vitro proliferation assays
Anti-proliferation effects in vitro
MC38-C215 cancer cells (5000 cells/well) were seeded in
96 well plates and the cultured cells treated with differ-
ent concentrations (1–10 μM) of tasquinimod for 72 h
under either normoxic or hypoxic growth conditions
(1 % O2 in a hypoxia incubator chamber; STEMCELL
Technologies, Grenoble, France). Viability was deter-
mined by MTT assay at the end of incubation.
Ex vivo suppression assay
CD4+ cell isolation: Naïve mouse spleens were pooled
and after blocking with Fc-block, incubated for 20 min
with 3 ml MACS buffer + 300 μl CD4-microbeads. The
cells were washed with MACS buffer and resuspended
in 2 ml MACS buffer prior to addition to an LS column
(LS+ for MidiMACS; Miltenyi). The column was washed
with MACS buffer and the CD4+ cells were eluted. The
cells were then added to 96-well plates for suppression
assay cultures. Suppression assay: CD4+ T cells isolated
from naïve mice (n = 3) were stimulated with Dynabeads
Mouse T-activators anti-CD3/-CD28 in the presence of
infiltrating F4/80+ cells, sorted by FACS from treated
and untreated MC38 tumors, in ratios of 1:1, 1:2, 1:4
and 1:8 (F4/80:CD4). Cell proliferation was measured by
[3H]-thymidine incorporation. Pulsing was performed
for 18 h with 0.5 μCi [3H]-dThd after 48 h incubation.
Quantitative Real-time PCR (qRT-PCR)
RNA was extracted from FACS-sorted F4/80+ cells that
were pre-isolated with anti-CD11b+ magnetic beads
fractions of single cell suspensions of tasquinimod
treated and untreated MC38-C215 tumors. RNA ex-
traction of CD11b+ was performed using the RNeasy
micro or mini kit according to the cell number (Qiagen,
Hilden, Germany). RNA in tumors was isolated from
100 μm of OCT-embedded tumor cryosections using
Trizol Reagent (Life Technologies). RNA concentration
and purity was determined through measurement of
A260/A280 ratios with a NanoDrop ND-1000 spectro-
photometer. RNA integrity was checked using the
Agilent 2100 Bioanalyzer. cDNA was prepared using
the iScript kit (BioRad, Hercules, CA, USA), or High-
Capacity cDNA Reverse Transcription Kit (Life Tech-
nologies) following the manufacturer’s instructions.
QPCR was performed with a two step PCR-protocol
(95 °C for 10 min, followed by 45 cycles of 95 °C for
10 s and 58 °C for 30 s) using SYBR Green (SsoFast
EvaGreen; BioRad) or 95 °C for 10 min, followed by
40 cycles of 95 °C for 10 s and 60 °C for 1 min using
Taqman gene expression (Life Technologies). Expression
levels were calculated as normalized ΔCt expression
values between target gene and the two “housekeeping”
genes β-Actin and Yhawz for Sybergreen technology
(Additional file 7: Table S1), and Hmbs and Cyclophilin A
for Taqman technology (Additional file 9: Table S3). The
primer sequences used for target genes, and the Taqman
probes references are listed in Additional files 8, 9 and 12:
Tables S2, S3 and S6.
Data were presented as fold induction (2ΔΔCt) of
treated tumors compared to control tumors levels (ΔΔCt).
Gene expression ex vivo
Purified CD11b+ cells was cultured ex vivo for 24 h in
DMEM medium ± IFNγ (2 ng/ml) and LPS (100 ng/ml)
in order to induce M1 macrophages to express Il-12β or
M2 macrophages to express Arg-1 [33, 34].
Cytokine determination by multiplex assay
Cytokines were extracted from 1 mm thick section of
frozen-embedded tumors, After thawing and 3 washes in
PBS, the pellet is suspended in PBS + Protease Inhibitor
Cocktail (Roche) and ground by ceramic beads in a
homogenizer (Fastprep, MP bio). Homogenate was then
passed through Qiashredder column (Qiagen) to reduce
viscosity. The different samples were assayed for protein
concentration and adjusted at 2 mg of protein/ml.
Cytokines were measured directly in nondiluted or
1/20 diluted tumor homogenate or in nondiluted mice
serum using Multiplex Immuno-assay kits (Milliplex
kit, Merck-Millipore) following manufacturer instruc-
tions. Signal detection was performed on Luminex
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200 (Luminex) and MFI (Median Fluorescence Inten-
sity) was recorded. The quantification for each cyto-
kine was detemined using standard curve analyzed
with a 5 Parameter Logistic model (XLfit software,
version 5.3, IDBS). For each cytokine in each assay,
Low Limit of Detection (LLOD) and Quantification
(LLOQ) were calculated. Statistical analysis on cyto-
kine levels were perfomed using Wilcoxon test or
Jonckheere-Terpstra test when the lower values were
between LLOD and LLOQ.
Statistical analysis
Normal data distribution was evaluated using the
Shapiro-Wilk test. The difference in tumor growth
over time between the two treatment groups was sta-
tistically evaluated by 2-way ANOVA analysis. In ex
vivo experiments, analysis of groups with different
treatment was analyzed using One-way ANOVA with
Dunnetts multiple comparison test or two-tailed stu-
dent’s t-test. For non-normal distributed data the
non-parametric Kruskal-Wallis or Mann-Whitney test
was used. Statistical analysis on cytokine levels were
perfomed using Wilcoxon test or Jonckheere-Terpstra
test when the lower values were between LLOD and
LLOQ. A p value less than 0.05 was considered statisti-
cally significant (* = p < 0.05; ** = p < 0.01; *** = p < 0.001).
Additional files
Additional file 1: Figure S1. Tasquinimod inhibits (A) the growth of
4T1 tumors and (B) metastasis at the dose of 30 mg/kg for 28 days of
treatment. The number of lung metastases per paraffin section (***p < 0.001;
t-test). The modulation of different subsets of infiltrating CD11b+ cells within
the tumor microenvironement was monitored by FACS analysis after
28 days following tumor cell inoculation. (C) Percent CD11b+ cells of
infiltrating cells and (D) F4/80+ cells as frequency of total CD11b+
cells. (E) Median Fluorescence Intensity (MFI) of CD206+ gated on
CD11b+ F4/80+, and (F) frequency of GR1+ cells of total CD11b+ cells;
Ly6ClowLy6G−, Ly6ChighLy6G− and Ly6ClowLy6G+ as frequency of total
CD11b+ cells. (G) A sustained shift in CD206 population over time
(*p < 0.05; two-way ANOVA, Error bars indicate s.e.m). (H) Down-regulation
of M2 markers in 4T1 tumors after tasquinimod treatment at days 14 and
28, (versus control; *p < 0.05, **p < 0.005, ***p < 0.001; two-way ANOVA, Error
bars indicate s.e.m). (PDF 71 kb)
Additional file 2: Figure S2. Modulation of myeloid CD11b+
subpopulations in spleen by tasquinimod. (A) Total CD11b+ cells in
the spleen from tumor bearing mice treated or non-treated with
tasquinimod in comparison to naïve non-treated mice, and (B) total
CD11b+ cells in the spleen from naïve mice after treatment with
tasquinimod (*p < 0.05 and **p < 0.01; t-test, Error bars indicate
s.e.m). (PDF 15 kb)
Additional file 3: Figure S3. Median Fluorescence Intensity (MFI) plots
of CD206, MHC-II and CD86 cell surface expression evaluated by flow
cytometry on isolated tumor infiltrating CD11b+ cells gated on the F4/
80high population after 1 and 3 days of in vivo exposure to tasquinimod.
Representative plots from one experiment are shown and dotted line
indicate aproximal median value for vehicle (*p < 0.05 and **p < 0.01;
One-way ANOVA with Kruskal-Wallis, Error bars indicate s.e.m). (PDF 79 kb)
Additional file 4: Figure S4. Serum levels of the IL-12(p40) cytokine
in tumor bearing mice exposed to tasquinimod for 1 up to 7 days
(* p < 0.05; t-test, Error bars indicate s.e.m). (PDF 11 kb)
Additional file 5: Figure S5. Tasquinimod inhibits MC38-C215 tumor
growth in a T cell independent manner. Nude mice were inoculated s.c.
with 0.5 × 106 MC38-C215 cells. Treatment with tasquinimod (30 mg/kg
ad lib.) was initiated on the day of tumor inoculation and continued
throughout the experiment (*p < 0.05; 2-way ANOVA). Tumor volume (left
panel) measurements and tumor weight at the end of experiment
(*p < 0.05; Mann Whitney) (right panel). (PDF 11 kb)
Additional file 6: Figure S6. Endothelial Colony Forming cells were
cultured on a layer of Adipocytes Stem cells maintened overnight at 37 °
C following Angiokit instructions (Essen Biosciences). Tasquinimod was
added in each well at different concentrations ranging from 1.56 to
50 μM in the presence of 4 ng/ml of recombinant VEGF-A (R&D). The
tube lengths of the formed vessels were monitored by Incucyte for at
least 80 h (Essen BioScience). Suramin or Anti-VEGF (R&D) are used as
positive controls for inhibition of tube vessel formation induced by VEGF-A.
(*** p < 0.001; 2-way ANOVA, Error bars indicate s.e.m). (PDF 28 kb)
Additional file 7: Table S1. Average raw Ct values for the different
genes analyzed in F4/80+ population using Syber Green Technology (PDF
29 kb)
Additional file 8: Table S2. Gene expression profiling in tumors treated
with tasquinimod after 1, 3, 5 and 7 days of exposure using Taqman
technology (Life technolgies). The results were presented as fold change
of treated tumors to control group levels. (PDF 95 kb)
Additional file 9: Table S3. Gene expression profiling in CD11b+
macrophages derived from tumors treated with tasquinimod after 1 and
3 days of exposure using Taqman technology (Life Technolgies). The
results were presented as fold change of treated tumors to control group
levels. (PDF 106 kb)
Additional file 10: Table S4. Fold change in protein expression levels
of treated tumors compared to control group after 1, 3, 5 and 7 days of
exposure using Luminex Technology. (p < 0.05; One way ANOVA).
(PDF 44 kb)
Additional file 11: Table S5. (A) Summary of tested kinases in different
cellular assays. The respective cell line, ligand, ligand concentration, and
duration of stimulation with the ligand are indicated. (B) Cellular IC50
values for indicated compounds on the inhibition of EGF-R, FGF-R2, IGF1-R,
KIT, MET, SRC, TIE 2, VEGF-R2 and VEGF-R3 kinase activity. Each compound
was tested in 8 different concentrations ranging from 33.0 × 10−11 to
1.0 × 10−5 (in duplicate). (PDF 70 kb)
Additional file 12: Table S6. List of probes used for mRNA
quantification using Syber Green technology. (PDF 26 kb)
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